References
- Schuknecht HF. Delayed endolymphatic hydrops. Ann Otol Rhinol Laryngol 1978;87:743–8.
- Schuknecht HF, Suzuka Y, Zimmermann C. Delayed endolymphatic hydrops and its relationship to Meniere's disease. Ann Otol Rhinol Laryngol 1990;99:843–53.
- Fukuoka H, Takumi Y, Tsukada K, Miyagawa M, Oguchi T, Ueda H, et al. Comparison of the diagnostic value of 3 T MRI after intratympanic injection of GBCA, electrocochleography, and the glycerol test in patients with Meniere's disease. Acta Otolaryngol 2012;132:141–5.
- Kasai S, Teranishi M, Katayama N, Sugiura M, Nakata S, Sone M, et al. Endolymphatic space imaging in patients with delayed endolymphatic hydrops. Acta Otolaryngol 2009;129:1169–74.
- Tanigawa T, Tamaki T, Yamamuro O, Tanaka H, Nonoyama H, Shiga A, et al. Visualization of endolymphatic hydrops after administration of a standard dose of an intravenous gadolinium-based contrast agent. Acta Otolaryngol 2011;131:596–601.
- Katahira N, Tanigawa T, Tanaka H, Nonoyama H, Ueda H. Diluted gadoteridol (ProHance®) causes mild ototoxicity in cochlear outer hair cells. Acta Otolaryngol 2013;133:788–95.
- Hashimoto S, Furukawa K, Sasaki T. Treatment of ipsilateral delayed endolymphatic hydrops. Acta Otolaryngol Suppl 1997;528:113–15.
- Nakashima T, Naganawa S, Teranishi M, Tagaya M, Nakata S, Sone M, et al. Endolymphatic hydrops revealed by intravenous gadolinium injection in patients with Ménière's disease. Acta Otolaryngol 2010;130:338–43.
- Food and Drug Administration. Public health advisory: gadolinium containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnecist, Pro-Hance, and MultiHance. Rockville, MD: FDA. 2006.
- Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586–92.
- Komatsuzaki A, Futaki T, Harada Y, Hozawa J, Ishii T, Kamei T, et al. Delayed endolymphatic hydrops. The guideline for standardization of diagnostic criteria in vertiginous diseases. The Committee for Standardization of Diagnostic Criteria in 16 Vertiginous Diseases. Equilib Res 1987;47:249–50; in Japanese.
- Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol 2006;41:206–12.
- Fang ZM, Chen X, Gu X, Liu Y, Zhang R, Cao DR, et al. A new magnetic resonance imaging scoring system for perilymphatic space appearance after intratympanic gadolinium injection, and its clinical application. J Laryngol Otol 2012;126:454–9.
- Egami N, Ushio M, Yamasoba T, Murofushi T, Iwasaki S. Indication of the side of delayed endolymphatic hydrops by vestibular evoked myogenic potential and caloric test. ORL J Otorhinolaryngol Relat Spec 2010;72:242–6.
- Ohki M, Matsuzaki M, Sugasawa K, Murofushi T. Vestibular evoked myogenic potentials in ipsilateral delayed endolymphatic hydrops. ORL J Otorhinolaryngol Relat Spec 2002;64:424–8.
- Tagaya M, Yamazaki M, Teranishi M, Naganawa S, Yoshida T, Otake H, et al. Endolymphatic hydrops and blood-labyrinth barrier in Ménière's disease. Acta Otolaryngol 2011;131:474–9.
- Takeda N, Koizuka I, Nishiike S, Kitahara T, Horii A, Uno A, et al. Clinical features in patients with delayed endolymphatic hydrops. Nihon Jibiinkoka Gakkai Kaiho 1998;101:1385–9.
- Kamiei T. Delayed endolymphatic hydrops – comparison with Meniere's disease. Pract Otol 2009;102:395–401.
- Mizuta K, Ito Y, Ushida J, Mori M, Kuze B, Hayakawa K, et al. Clinical characteristics of delayed endolymphatic hydrops. Equilib Res 1998;57:328–34.